Background: Treatment of chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based to IFN-free directly acting antiviral (DAA) regimens. IFN-based therapy causes treatmentinduced cytopenias, while cellular changes on DAA therapy are not well described. Because cellular changes on DAA therapy may reflect the host response to viral decline rather than a treatment side effect, we explored changes in peripheral cell populations during two DAA trials conducted at the NIAID. Methodology: We evaluated chronic HCV genotype-1 treatment-naive patients treated with sofosbuvir/ribavirin for 24 weeks (SPARE trial, n=55) or sofosbuvir/ledipasvir for 12 weeks (SYNERGY trial Arm A, n=20). Peripheral cell populations were quantitated by flow cytometry and results were analyzed using a mixed model (SPARE) or by non-parametric ANOVA (SYNERGY). Chemokine receptor expression was measured by flow cytometry and serum chemokines were quantitated by ELISA. Histologic inflammation was quantitated on paired pre- and post-treatment liver biopsies where available. Viral load was measured using the Roche assay. Results: Treatment led to rapid HCV decline, with 96% and 90% of patients on SPARE and SYNERGY Arm A, respectively, achieving undetectable viral load by week 4. The pro-inflammatory chemokine IP-10 (SPARE) and hepatic AST/ALT (SPARE, SYNERGY) normalized in most patients within 10 days of initiating therapy. B -cells and neutrophils increased from baseline and peaked 1-2 weeks into therapy; the increase in neutrophils was maintained through therapy while the increase in B-cells was transient (Figure 1). Detailed evaluation of B-cells from 12 SPARE patients at day 7-10 of treatment revealed higher surface expression of CXCR3 (p = 0.049) and CCR6 (p = 0.029), but not CCR4 or CXCR4, compared to baseline. By end of treatment, levels of both receptors had normalized. For CXCR3, this early increase was most notable on activated (p = 0.049) and resting memory B cells (p = 0.0044). Histologic hepatic inflammation decreased in 36/39 patients (SPARE) and 4/4 patients (SYNERGY) with paired biopsies. Conclusions: In these DAA-based HCV treatment trials there is an early decline in IP-10, increase in peripheral B-cells, and increase in CXCR3 expression on peripheral memory B-cells. These data suggest a dynamic reduction in hepatic immigration and/or increase in hepatic egress of tissue-resident CXCR3- expressing B-cells associated with suppression of HCV.